Wang Y, Casarin S, Daher M, Mohanty V, Dede M, Shanley M
bioRxiv. 2025; .
PMID: 40027823
PMC: 11870559.
DOI: 10.1101/2025.02.17.638701.
Samper N, Hardardottir L, Depierreux D, Song S, Nakazawa A, Gando I
Front Immunol. 2024; 15:1490250.
PMID: 39687626
PMC: 11646858.
DOI: 10.3389/fimmu.2024.1490250.
McErlean E, McCarthy H
J Nanobiotechnology. 2024; 22(1):552.
PMID: 39256765
PMC: 11384716.
DOI: 10.1186/s12951-024-02746-4.
Badhrinarayanan S, Cotter C, Zhu H, Lin Y, Kudo M, Li D
Future Oncol. 2024; 20(28):2049-2057.
PMID: 38861301
PMC: 11497967.
DOI: 10.1080/14796694.2024.2355863.
Lenart M, Rutkowska-Zapala M, Siedlar M
Clin Exp Immunol. 2024; 217(2):151-158.
PMID: 38767592
PMC: 11239562.
DOI: 10.1093/cei/uxae045.
synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.
Lupo K, Yao X, Borde S, Wang J, Torregrosa-Allen S, Elzey B
Nat Commun. 2024; 15(1):1909.
PMID: 38429294
PMC: 10907695.
DOI: 10.1038/s41467-024-46343-3.
γδ T cells mediate robust anti-HIV functions during antiretroviral therapy regardless of immune checkpoint expression.
Field K, Wragg K, Kent S, Lee W, Juno J
Clin Transl Immunology. 2024; 13(2):e1486.
PMID: 38299190
PMC: 10825377.
DOI: 10.1002/cti2.1486.
Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma.
Kim S, Chung H, Kwak J, Kim Y, Park C, Kim Y
J Immunother Cancer. 2024; 12(1).
PMID: 38191242
PMC: 10806558.
DOI: 10.1136/jitc-2023-007886.
Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies.
Hasan M, Campbell A, Croom-Perez T, Oyer J, Dieffenthaller T, Robles-Carrillo L
J Immunother Cancer. 2023; 11(12).
PMID: 38081778
PMC: 10729131.
DOI: 10.1136/jitc-2023-007502.
TIGIT contributes to the regulation of 4-1BB and does not define NK cell dysfunction in glioblastoma.
Lupo K, Torregrosa-Allen S, Elzey B, Utturkar S, Lanman N, Cohen-Gadol A
iScience. 2023; 26(12):108353.
PMID: 38053639
PMC: 10694670.
DOI: 10.1016/j.isci.2023.108353.
Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care.
Xiao Y, Li Z, Zhong N, Cao L, Liu B, Bu L
Transl Oncol. 2023; 38:101794.
PMID: 37820473
PMC: 10582482.
DOI: 10.1016/j.tranon.2023.101794.
Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome.
Guo X, Yu S, Ren X, Li L
Heliyon. 2023; 9(9):e19222.
PMID: 37810157
PMC: 10558320.
DOI: 10.1016/j.heliyon.2023.e19222.
Decreased expression of TIGIT on CD14 + monocytes correlates with clinical features and laboratory parameters of patients with primary Sjögren's syndrome.
Zhao P, Peng C, Chang X, Cheng W, Yang Y, Shen Y
Clin Rheumatol. 2023; 43(1):297-306.
PMID: 37749409
DOI: 10.1007/s10067-023-06759-6.
In vitro vascular differentiation system efficiently produces natural killer cells for cancer immunotherapies.
Galat Y, Du Y, Perepitchka M, Li X, Balyasnikova I, Tse W
Oncoimmunology. 2023; 12(1):2240670.
PMID: 37720687
PMC: 10501168.
DOI: 10.1080/2162402X.2023.2240670.
The Increased TIGIT-Expressing CD3CD56 Cells Are Associated with Coronary Artery Disease and Its Inflammatory Environment.
Xiong X, Duan Z, Zhou H, Huang G, Niu L, Jin Y
Inflammation. 2023; 46(5):2024-2036.
PMID: 37491572
DOI: 10.1007/s10753-023-01859-6.
Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity.
Zheng P, Dou Y, Wang Q
Front Cell Infect Microbiol. 2023; 13:1206720.
PMID: 37424786
PMC: 10324618.
DOI: 10.3389/fcimb.2023.1206720.
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment.
Ziogas D, Theocharopoulos C, Lialios P, Foteinou D, Koumprentziotis I, Xynos G
Cancers (Basel). 2023; 15(10).
PMID: 37345056
PMC: 10216291.
DOI: 10.3390/cancers15102718.
TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies.
Hasan M, Croom-Perez T, Oyer J, Dieffenthaller T, Robles-Carrillo L, Eloriaga J
Cancers (Basel). 2023; 15(10).
PMID: 37345049
PMC: 10216728.
DOI: 10.3390/cancers15102712.
Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms.
Soldi L, Silva V, Rabelo D, Uehara I, Silva M
J Cancer Res Clin Oncol. 2023; 149(9):6661-6673.
PMID: 36633682
DOI: 10.1007/s00432-023-04575-8.
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
Irani Y, Kok C, Clarson J, Shanmuganathan N, Branford S, Yeung D
Blood Adv. 2023; 7(11):2364-2374.
PMID: 36622326
PMC: 10220272.
DOI: 10.1182/bloodadvances.2022008854.